ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Efficacy and Safety of PCSK-9 Inhibitor, Evolocumab for Lipid Management in Kidney Transplant Recipients

J. Pandav1, R. Saranu1, S. Muhsin1, N. Murakami1, S. Gabardi1, K. Safa2, A. Chandraker1

1Renal division, Brigham and Women's Hospital, Boston, MA, 2Renal division, Massachusetts General Hospital, Boston, MA

Meeting: 2022 American Transplant Congress

Abstract number: 770

Keywords: Dyslipidemia, Kidney transplantation

Topic: Clinical Science » Kidney » 35 - Kidney: Cardiovascular and Metabolic Complications

Session Information

Session Name: Kidney: Cardiovascular and Metabolic Complications

Session Type: Poster Abstract

Date: Saturday, June 4, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 5:30pm-7:00pm

Location: Hynes Halls C & D

*Purpose: Dyslipidemia is common in kidney transplant recipients (KTRs). KDIGO guidelines suggest all KTRs should be treated with statins due to the high risk of ischemic heart disease. However, due to myopathy, hepatotoxicity, and interactions with calcineurin inhibitors (CNIs), statins are less well tolerated in KTRs. Proprotein convertase subtilisin/Kexin type 9 (PCSK-9) inhibitors is a novel FDA-approved medication class used for the treatment of low-density lipoprotein-cholesterol (LDL-C). The use of these agents has not been studied in KTRs. Our study was aimed at evaluating the efficacy and safety of PCSK-9 inhibitor, Evolocumab in KTRs.

*Methods: KTRs at least 1-year post-transplant with baseline LDL-C levels >100 mg/dL or >70 mg/dL with risk factors such as diabetes, coronary artery disease, or smoking were eligible for the study. Baseline lipid panel was checked and ASCVD scores were calculated after which they were started on Evolocumab 140 mg subcutaneously every 2 weeks. Patients previously on statin therapy were asked to continue their medication. At the end of 3 months, lipid panel, ASCVD scores, and kidney function were checked. The total target enrollment is 120 patients with a follow-up period of 1 year. Lipoprotein A, Apolipoprotein A1/B, CPK, and LFTs and tacrolimus levels are also being followed. Currently, 30 patients are consented and 12 patients have completed 3 months follow up.

*Results: At the end of 3 months of treatment, all 12 patients demonstrated a significant drop in their LDL-C levels (35% to 90%). There was also a remarkable reduction in ASCVD scores (37% to 80%). The mean eGFR for all patients was stable. Overall, Evolocumab was well tolerated by all patients. One patient had a local allergic reaction, treatment was stopped and they were excluded from the study. None of the other 12 patients reported any major adverse reactions.

*Conclusions: PCSK-9 inhibitors are very effective for the reduction of LDL-C levels in KTRs. They have a favorable side effect profile and do not interact with immunosuppressive medications. Their effect on the reduction of LDL-C levels also correlates with an improvement in ASCVD score, which was clearly demonstrated in this study. Unlike statins, which have shown cardiovascular benefits in long-term studies, there is no data regarding PCSK-9 inhibitors as trials are still underway. Our analysis is a part of an ongoing prospective study that is aimed at studying the long-term benefits of PCSK-9 inhibitors on LDL-C levels and allograft function.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Pandav J, Saranu R, Muhsin S, Murakami N, Gabardi S, Safa K, Chandraker A. Efficacy and Safety of PCSK-9 Inhibitor, Evolocumab for Lipid Management in Kidney Transplant Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/efficacy-and-safety-of-pcsk-9-inhibitor-evolocumab-for-lipid-management-in-kidney-transplant-recipients/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences